By Shah Newaz
Beximco Pharmaceuticals Limited launched distribute breast cancer drug “OgivriTM” of Dutch Mylan Pharma aiming to make it available in Bangladeshi market.
“The first product, OgivriTM, a breast cancer drug is biosimilar to blockbuster drug Herceptin from Roche with global sales in excess of $7 billion in 2018. Ogivri is approved by the U.S. Food and Drug Administration and has also received marketing authorisation from the European Medicines Agency”, said Beximco Pharma website.
Cancer is now one of the leading causes of death in Bangladesh and currently there are more than 50,000 HER2-positive breast cancer patients in the country.
Beximco Pharma announces a Commercial Agreement with Mylan under which Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to treat different types of cancers, rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other medical conditions.
Beximco, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces the signing of a commercial agreement for distribution of certain products of Mylan in Bangladesh.
Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, said Beximco incredibly excited to announce this commercial agreement with Mylan, the first of its kind in Bangladesh.
“With one of the largest and most diverse portfolios of biosimilars approved in more than 80 countries, Mylan is the ideal partner for Beximco Pharma as we enter the key therapeutic areas covered by biosimilar products. This unique partnership, which combines world-class product development, marketing and regulatory expertise, will introduce a portfolio of biologics, in particular, target-specific high-value monoclonal antibodies, in Bangladesh. Together, we will be able to provide our patients with more affordable access to these much-needed products.” He added.
Rakesh Bamzai, President, India and Emerging Markets, Mylan said, “The growing incidence of breast cancer is a major public health concern among women in Developing Markets. As a global leader in the development of complex products, including biosimilar medicines, Mylan, through its commercial agreement with Beximco Pharmaceuticals, is pleased to make Trastuzumab accessible to patients in Bangladesh.”
Beximco Pharma is a leading exporter of pharmaceuticals in Bangladesh. The Company currently has a global footprint in more than 50 countries and has been accredited by the leading global regulatory authorities including U.S. FDA, Malta Medicines Authority (EU), TGA (Australia), Health Canada, GCC (Gulf) and TFDA (Taiwan).
Mylan N.V. is a global generic and specialty pharmaceuticals company domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a “Global Center” in Canonsburg, Pennsylvania, US.